Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Staging prostate cancer--1997: current methods and limitations

D G Bostwick1

  • 1Department of Pathology, Mayo Clinic, Rochester, MN 55905, USA. bostwick.david@mayo.edu

European Urology
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High grade prostatic intraepithelial neoplasia with squamous differentiation.

Journal of clinical pathology·2006
Same author

Basal cell hyperplasia and basal cell carcinoma of the prostate: a comprehensive review and discussion of a case with c-erbB-2 expression.

Journal of clinical pathology·2005
Same author

Classification and grading of the non-invasive urothelial neoplasms: recent advances and controversies.

Journal of clinical pathology·2003
Same author

Prostatic intraepithelial neoplasia.

Current urology reports·2002
Same author

Comparison of renal ablation with cryotherapy, dry radiofrequency, and saline augmented radiofrequency in a porcine model.

Journal of the American College of Surgeons·2001
Same author

Molecular genetic evidence for different clonal origin of components of human renal angiomyolipomas.

The American journal of surgical pathology·2001

Accurate prostate cancer staging is crucial for effective treatment. Current TNM staging methods have limitations in precision, impacting treatment decisions and patient outcomes, necessitating improved diagnostic approaches.

Area of Science:

  • Urology
  • Oncology
  • Pathology

Background:

  • Clinical and pathologic staging of prostate cancer determines tumor extent using the TNM system.
  • Staging stratifies patients based on detection methods: incidental, digital rectal exam, or PSA/ultrasound.
  • Current staging faces significant understaging (up to 59%) and overstaging (up to 5%) challenges.

Purpose of the Study:

  • To evaluate current clinical and pathologic staging of prostate cancer, focusing on early stages for curative potential.
  • To highlight limitations in current staging accuracy and its impact on treatment efficacy and outcomes.
  • To discuss proposed improvements for more precise prostate cancer staging.

Main Methods:

  • Review of the TNM staging system for prostate cancer.

Related Experiment Videos

  • Analysis of discrepancies between clinical and pathologic staging.
  • Examination of proposed improvements such as preoperative biopsies and prognostic indices.

    • Main Results:

    • The TNM system is widely used but has limitations in accurately reflecting tumor burden.
    • Clinical understaging is a significant issue, potentially leading to suboptimal treatment selection.
    • Proposed staging improvements aim to enhance accuracy and reduce uncertainty.

    Conclusions:

    • Current prostate cancer staging methods require improvement to accurately guide treatment and predict outcomes.
    • Enhanced staging accuracy, particularly in early stages, is essential for maximizing cure rates.
    • International agreement on pathologic staging facilitates comparative treatment research.